2025 Annual Meeting | Industry Therapeutic Update from Eisai Inc.: Talking with Patients and Care Partners About Early AD Treatment: Communicating the Rationale for Early, Ongoing Therapy
Date
Sunday 04/06/25
Time
11:45 AM - 12:45 PM PDT
Add To Calendar
Location
San Diego Convention Center | 6CF
Session Format
This program will be presented in-person only
On Demand
This program is not expected to be available in the meeting's On Demand product.
Event Type
Industry Therapeutic Update
Topic(s)
General Neurology, Aging, Dementia, and Behavioral Neurology
Learning Objectives
The earlier that mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia are identified and treated, the greater the opportunity for patient benefit. Further, because AD is a progressive neurodegenerative disease and toxic proteins continue to accumulate over time, ongoing treatment is critical. This program takes a case-based approach to exploring the benefits of a treatment option for early AD and discussing the rationale for early and ongoing therapy with patients and care partners.
CME Available
No CME available
Program Materials
Program Evaluations
Event Timeline
11:45 AM - 12:45 PM PDT
Speaker
Industry Therapeutic Update from Eisai Inc.: Talking with Patients and Care Partners